In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Acute heart failure: novel therapies on the horizon
Session

Event : Heart Failure 2015

Topic : Acute Heart Failure– Treatment

  • Session type : Symposium
  • Date : 23 May 2015
  • Time : 14:15 - 15:45

7 presentations in this session

Serelaxin.

Event : Heart Failure 2015

  • Session : Acute heart failure: novel therapies on the horizon
  • Speaker : JR Teerlink (San Francisco,US)

TRV027: a biased ligand approach to improve outcomes.

Event : Heart Failure 2015

  • Session : Acute heart failure: novel therapies on the horizon
  • Speaker : GM Felker (Durham,US)

Ularitide: this time it is different.

Event : Heart Failure 2015

  • Session : Acute heart failure: novel therapies on the horizon
  • Speaker : S Anker (Berlin,DE)

Use of adjuncts in AHF: potassium binders.

Event : Heart Failure 2015

  • Session : Acute heart failure: novel therapies on the horizon
  • Speaker : A Mebazaa (Paris,FR)

Novel mineralocorticoid receptor antagonists.

Event : Heart Failure 2015

  • Session : Acute heart failure: novel therapies on the horizon
  • Speaker : B Pitt (Ann Arbor,US)

Cardiac myosin activators.

Event : Heart Failure 2015

  • Session : Acute heart failure: novel therapies on the horizon
  • Speaker : J Cleland (Glasgow,GB)

Panel discussion.

Event : Heart Failure 2015

  • Session : Acute heart failure: novel therapies on the horizon

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are